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The HIV-1 Tat protein activates transcription of the viral LTR promoter through interaction with the nuclear transcription
machinery of the host cell. Tat can also activate the LTR promoter in a paracrine or inter-cellular manner by a yet unknown
mechanism. One possibility is that Tat protein itself is secreted by cells and taken up by other cells. According to this
mechanism, inter-cellular transcriptional activation by Tat should be very similar to intra-cellular trans-activation in Tat-
producing cells. A large number of cytokine genes was recently reported to be Tat-responsive, raising the possibility that
such cytokines and the corresponding cellular transduction pathways are involved in inter-cellular Tat action. The transcrip-
tional events in such an indirect route are likely to differ from intra-cellular Tat action. To discriminate between a direct or
indirect mechanism of inter-cellular Tat action, we compared the activity of a set of Tat mutants and different promoter
constructs in inter-cellular and intra-cellular transcriptional activation. Identical results were obtained in both assays, sug-
gesting that Tat protein itself is exported by one and transported into the nucleus of another cell. The demonstration that
Tat antibodies specifically inhibit the inter-cellular route is also consistent with cell-to-cell transport of the Tat protein.
Furthermore, we found that the second Tat coding exon, including the RGD motif that has been proposed to interact with
an integrin receptor, is not required for cellular uptake of the Tat protein. q 1996 Academic Press, Inc.
INTRODUCTION (Herrmann and Rice, 1993, 1995), a factor with Tat-com-
plementing activity in cell-free transcription assays (Zhou
The human immunodeficiency virus type 1 (HIV-1) Tat
and Sharp, 1995) and other proteins (Fridell et al., 1995).
protein is a potent activator of viral gene expression and
TAR-binding proteins include the loop-specific proteinreplication (Luciw, 1996). Tat is a nuclear protein (Hauber
TRP-185, RNA polymerase II, and other putative cofactorset al., 1989; Ruben et al., 1989; Hauber et al., 1987; Chin et
(Wu et al., 1991; Sheline et al., 1991; Gatignol et al., 1991;al., 1991) that is brought in proximity to the transcription
Wu-Baer et al., 1996). In addition, the Tat-response ismachinery because of its ability to bind to the TAR RNA
likely to entail several protein–protein contacts betweenhairpin structure as part of the nascent transcript (Berk-
the Tat- and TAR-associated factors and the generalhout et al., 1989; Dingwall et al., 1989). Mutational analy-
DNA-binding transcription factors and transcriptional ac-ses have shown that Tat-activation requires not only the
tivators, including NF-kB, Sp1, TBP, and LBP-1 (Ka-trinucleotide bulge that forms the actual Tat binding site,
shanchi et al., 1994; Wu-Baer et al., 1995; Veschambrebut also the apical loop and the stem domain of TAR
et al., 1995; Jeang et al., 1993; Keen et al., 1996; MavankalRNA (Feng and Holland, 1988; Cordingley et al., 1990;
et al., 1996).Dingwall et al., 1990; Roy et al., 1990; Weeks and Croth-
Several assays were developed to study the mecha-ers, 1991; Garcia et al., 1989; Berkhout and Jeang, 1989;
nism of Tat-mediated transcriptional activation. The stan-Berkhout and Jeang, 1991; Klaver and Berkhout, 1994a).
dard Tat assay involves cotransfection of a Tat-expres-The molecular mechanism by which Tat activates HIV-1
sion vector and an LTR-CAT reporter construct. Proteingene expression has been the subject of intense investi-
transfection methods such as ‘‘scrape-loading’’ (Frankelgation (Cullen, 1993). Tat activates transcription of the
and Pabo, 1988; Gentz et al., 1989) and electroporationlong terminal repeat (LTR) promoter by increasing the
(Kashanchi et al., 1992; Verhoef et al., 1993) have alsoefficiency of transcriptional initiation as well as increas-
been developed to introduce Tat protein into tissue cul-ing the efficiency of transcriptional elongation. Numerous
ture cells. It is believed that these procedures transientlycellular factors were proposed to be involved in Tat-medi-
damage cell membranes, allowing molecules in the me-ated activation of transcription. These proteins bind ei-
dium to enter the cytoplasm. Surprisingly, it was alsother to Tat itself or to the TAR RNA structure. Candidate
found that Tat, either the recombinant form produced inTat-binding factors include a cellular protein kinase
Escherichia coli or a synthetic peptide, can be taken up
by cells in vitro. The current idea is that Tat subsequently1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (31-20) 6916531. enters the nucleus, leading to trans-activation of the HIV-
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1 LTR promoter (Green and Loewenstein, 1988; Frankel a mechanism for virus escape from the host immune
response. These Tat effects were observed primarily inand Pabo, 1988; Mann and Frankel, 1991; Frankel et al.,
1989). Furthermore, Tat is released into the extracellular tissue culture experiments, but similar results were re-
cently reported in transgenic mice (Brady et al., 1995).medium during acute infection of T cells by HIV-1 or after
transfection of a Tat expression plasmid (Ensoli et al., Deregulation of cellular genes by Tat may explain the
observation that numerous cytokine levels are elevated1993). These combined results suggest that transcrip-
tionally active Tat protein can be secreted from one and in the serum of HIV-1-infected individuals (reviewed in
(Chang et al., 1995)). In this study, we tested whethertaken up by a second cell (‘‘inter-cellular’’ trans-activa-
tion), although little detail on the molecular mechanisms soluble cellular factors and/or cytokines are involved in
inter-cellular LTR-activation. The results indicate that Tatof Tat protein secretion and uptake is currently available.
HIV-infected T cells and Tat plasmid-transfected COS protein itself is exported and taken up by cells.
cells were found to secrete substantial quantities of Tat
protein by an unknown mechanism (Ensoli et al., 1993). MATERIALS AND METHODS
The absence of a recognizable signal sequence in Tat
Cell lines and plasmidsdoes not rule out protein secretion because a number
of growth factors lack such signals (Acland et al., 1990). The lymphocytic T cell line SupT1 was maintained at
Cellular uptake of Tat was suggested to occur through 377 and 5% CO2 in RPMI 1640 medium containing 10%
binding of Tat to the cell surface via specific (receptor- fetal calf serum (FCS). COS cells were grown in Dulbec-
mediated) interactions. In particular, the C-terminal Tat co’s modified Eagle’s medium with 10% FCS. The LTR-
domain encoded by the second coding exon (‘‘exon 2’’) CAT reporter construct was described previously (3*LTR-
contains the arginine–glycine–aspartate sequence (the CAT in (Klaver and Berkhout, 1994b). The Tat-expression
RGD motif) that is present in extracellular matrix proteins plasmid pcDNA3-Tat contains the Tat-Rev genomic seg-
and responsible for cell adhesion through binding to inte- ment of the HIV-1 isolate pLAI (Peden et al., 1991) in-
grin receptors (Brake et al., 1990a; Barillari et al., 1993). serted downstream of the cytomegalovirus immediate
The in vivo biological relevance of these inter-cellular early promoter in pcDNA3 (Invitrogen). Details of this
effects of Tat is yet unknown, but there may be situations vector and the mutagenesis protocol will be described
where extracellular Tat reaches sufficient concentra- elsewhere (Verhoef and Berkhout, in preparation). The
tions to influence transcription in other cells. For in- SV40-CAT and CMV-CAT plasmids were described pre-
stance, extracellular Tat may activate HIV-1 gene ex- viously (Koken et al., 1994). The RSV-Luc plasmid con-
pression in cells infected with a Tat-defective provirus. tains the Luciferase reporter gene under transcriptional
Paracrine Tat may also affect the physiology of unin- control of the Rous sarcoma virus LTR promoter and was
fected cells by deregulation of cellular gene expres- kindly provided by Dr. Hans Pannekoek (Department of
sion (see below). Biochemistry, University of Amsterdam). Mutants of the
Transcriptional activation by Tat was initially believed HIV-1 LTR-CAT construct with specific base substitutions
to be highly specific for the HIV-1 LTR promoter because in the TAR bulge and loop domains were described pre-
of strict requirements for both the unique TAR RNA at- viously (Berkhout and Jeang, 1991).
tachment site in the nascent transcript (Berkhout et al.,
1989) and a specific set of upstream promoter-enhancer Transfections
motifs (Berkhout et al., 1990). However, Tat can trans-
activate the LTR in a TAR-independent manner under Transient transfections were performed with DEAE-
dextran (COS cells; see (Berkhout and Jeang, 1989)) orcertain circumstances (Harrich et al., 1990; Taylor et al.,
1992) and Tat can also modulate the expression of a by means of electroporation (SupT1 T cells, see (Das et
al., 1995)). In a typical inter-cellular Tat assay, COS cellsvariety of cellular genes (Chang et al., 1995). For instance,
Tat stimulates immunoregulatory cytokine genes includ- (80% confluency on 60-mm dishes) were transfected with
10 mg pcDNA3-Tat plasmid (wild-type or mutant) anding tumor necrosis factors a and b (TNFa and TNFb)
(Buonaguro et al., 1992, 1994; Sastry et al., 1990), trans- SupT1 cells (5 1 106) with 10 mg LTR-CAT. The trans-
fected cells were cultured in RPMI medium with 10% FCSforming growth factor a1 and b1 (TGFa1 and TGFb1
(Cupp et al., 1993; Lotz et al., 1994; Nabell et al., 1994; for 24 hr. After being washed, the T cells were resus-
pended and added to the dish with COS cells in a totalZauli et al., 1993b), the interleukins IL-2 and IL-6 (Purvis
et al., 1992; Hofman et al., 1993; Iwamoto et al., 1994; volume of 5 ml. Fresh medium (2 ml) was added 48 hr
after transfection and the SupT1 cells in the supernatantScala et al., 1994; Zauli et al., 1993a), and Tat activates
several cytokine receptors including IL-2Ra and IL-4R were harvested at 72 hr posttransfection. Cell extracts
were prepared and assayed for CAT activity as described(Purvis et al., 1992). Tat also decreases transcription of
cellular genes. For instance, down-regulation of the ma- (Seed and Sheen, 1988). CAT activities were quantitated
in the linear range of acetylation. For the Luciferasejor histocompatibility complex class I gene (MHCI) has
been reported (Howcroft et al., 1993), which may provide assay, SupT1 T cells were collected by centrifugation
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and resuspended in 50 ml 100 mM K-phosphate buffer
(pH 7.8), and then DTT was added to 5 mM. Cells were
lysed by three cycles of freeze-thawing (1 min 0807 in
CO2/ethanol and 2 min 377), and the extract was cleared
by centrifugation. Extract (20 ml) was mixed with 280 ml
buffer (25 mM glycylglycine, pH 7.8, 15 mM MgSO4, 3.3
mM ATP, 100 mg/ml BSA) and the reaction was initiated
by addition of 100 ml luciferin (Sigma). Light emission
was measured for 10 sec in a luminometer.
For cocultivation in the absence of COS-SupT1 cell –
cell contact, the COS cells were seeded and transfected
with 5 mg pcDNA3-Tat in 35-mm Transwell plates
(Costar). At the same time, 2.5 1 106 SupT1 cells were
transfected with 5 mg LTR-CAT. At Day 1 posttransfection,
the T cells in 2.5 ml RPMI were added to the upper
compartment of the Transwell plate. Fresh medium (1
FIG. 1. Schematic of four potential routes for inter-cellular Tat-medi-ml) was added at 48 hr posttransfection and the SupT1
ated activation of the viral LTR promoter. The top panel shows intra-
cells were harvested after 72 hr. In other experiments, cellular activation of the HIV-1 LTR promoter by Tat protein produced
cocultivation was performed in the presence of Tat-spe- in a cotransfected SupT1 cell. The bottom panel shows the Tat-produc-
ing COS cell (donor cell) that is cocultured with an LTR-CAT-transfectedcific antibodies. Subconfluent COS cells in 35-mm dishes
SupT1 cell (acceptor cell). Tat is secreted by COS cells in routes 1 andwere transfected with 5 mg pcDNA3-Tat, whereas several
2, followed either by uptake in SupT1 cells and nuclear transport (theindependent SupT1 transfections (10 mg LTR-CAT/5 1
direct route 2) or activation of a putative cellular cofactor Z (route 1,
106 cells) were pooled after 24 hr and split such that see text for details). According to the hypothetical routes 3 and 4, Tat
each COS dish received 2.5 1 106 transfected SupT1 activates the expression of a secreted cofactor X in COS cells. This
cytokine-like factor subsequently activates transcription in SupT1 cellscells in 2.5 ml RPMI. The transfected SupT1 cells were
through direct or indirect pathways (routes 3 and 4, respectively, withfirst mixed with the antibody solution, and subsequently
involvement of cofactor Y in the latter scenario).added to the Tat-producing COS cells. Regular cotrans-
fections (intra-cellular assay) were performed in SupT1
cells with 1 mg pcDNA3-Tat and 2 mg LTR-CAT.
in the inter-cellular route is generally considered to be di-
rect with cellular secretion and uptake of Tat protein, whichWestern blotting
is supposed to interact with cellular transcription factors in
COS cells (80% confluency, 90-mm dish) were trans- the nucleus of the acceptor cell (route 2 in the schematic
fected with 10 mg of the indicated pcDNA3-Tat con- of Fig. 1). However, indirect routes involving cellular factors
structs. Cells were washed in phosphate-buffered sa- either in the donor or acceptor cell can be envisaged. First,
line (PBS) after 3 days and resuspended in 1 ml 21 secreted Tat may activate a signal transduction pathway
SDS sample buffer. Proteins were resolved on a 20% in the acceptor cell by interaction with a cell surface recep-
SDS – polyacrylamide gel and transferred to Immobi- tor or, upon entering of the cell, by interaction with a cyto-
lon-P (Millipore) at 60 V for 16 hr. The membrane was solic protein (putative cofactor Z in route 1). A putative target
subsequently blocked with 5% nonfat dry milk in PBS for Tat are the integrin receptors, signalling molecules that
buffer with 0.05% Tween-20, incubated with Tat mono- transmit information from the extracellular domain to the
clonal antibodies (diluted 1 in 1000 in PBS), kindly pro- cytoplasmic domain via a number of signalling pathways
vided by Dr. C. Debouck (Brake et al., 1990b), and de- including PKC, MAP kinases, changes in intracellular pH,
veloped with the BCIP-NBT protocol as described (Das calcium concentration, and membrane potential (Schwartz
et al., 1995) (Table 1). et al., 1995). Alternatively, Tat may enter the acceptor cell
and interact with a regulatory cofactor, e.g., the Tat-associ-
RESULTS ated protein kinase (Herrmann and Rice, 1995). Second,
because Tat induces a large number of cellular proteinsSeveral hypothetical routes for inter-cellular Tat
with a paracrine function in the producer cell (see Introduc-action
tion), these cellular proteins may play a role in the inter-
cellular mechanism. The Tat-induced cytokines may affectIn contrast to the regular Tat-assay that occurs within
one cell (‘‘intra-cellular’’), we will refer to the two-cell Tat gene expression in the acceptor cell through direct or indi-
rect pathways (routes 3 and 4, with a Tat-induced cytokinemechanism as the ‘‘inter-cellular’’ Tat assay (Fig. 1). The
Tat-transfected cell that expresses Tat protein is the ‘‘donor X and a cofactor Y). For instance, the Tat-induced cytokine
TNF can activate the transcription factor NF-kB in the ac-cell’’ and the LTR-CAT-transfected cell is the ‘‘acceptor cell’’.
The mechanism by which Tat modulates gene expression ceptor cell (Westendorp et al., 1995).
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FIG. 2. Inter-cellular Tat activity requires direct cell–cell contact. (A) Dose–response curve of LTR-CAT activation in SupT1 cells upon coculture
with COS cells transfected with increasing amounts of the Tat plasmid. (B) Culture of SupT1-LTR-CAT cells with mock-transfected (0 Tat) or Tat-
transfected COS cells. The two cell types were cocultured in the presence or absence of a 0.45-mm filter (//0 membrane).
The activity of Tat mutants is similar in intra- versus Tat mutants are expected to differ in their transcriptional
activation capacity in the two assay systems. It is im-inter-cellular LTR-activation
portant to include partially defective Tat mutants in this
The inter-cellular Tat assay involves the coculture of comparative analysis. Many of the previously described
Tat-producing cells and LTR-CAT-containing cells. This Tat mutants are completely inactive (Jeang, 1995) and
assay is schematically depicted in Fig. 1 and was per- the potential problem with such mutants is that their
formed essentially as described in previous studies (Hel- conformation may be affected so dramatically that they
land et al., 1991; Marcuzzi et al., 1992a; Marcuzzi et al., will be fully inactive in all assays. Partially defective Tat
1992b). In brief, adherent COS cells were transfected mutants will be more informative in this comparative
transiently with the pcDNA3-Tat plasmid and nonadher- analysis.
ent SupT1 cells were transfected with the LTR-CAT re- Four conserved aromatic amino acids within the Cys-
porter. When SupT1 reporter cells were cocultivated for teine-rich and core domains of the HIV-1 Tat protein were
48 hr with the COS-Tat cells, a 4- to 20-fold increase in individually replaced by aromatic or nonaromatic amino
CAT activity was consistently observed (e.g., Figs. 2A and acids. The mutant proteins were named by appending
2B). Titration of the pcDNA3-Tat plasmid demonstrates the amino acid present in wild-type Tat, the residue num-
a linear response of LTR-induced transcription in the ber, and the amino acid present in the mutant at this
acceptor SupT1 cells (Fig. 2A). Cocultivation with a mem- position. The LTR-trans-activation capacity of these mu-
brane that prevents cell-to-cell contact abolished inter- tants in a standard intra-cellular assay in SupT1 cells is
cellular Tat activation (Fig. 2B). This result is consistent presented in Fig. 3A. A complete spectrum of activities
with published evidence (Helland et al., 1991) and indi- was obtained with this set of Tat mutants. For instance,
cates a strict requirement for cell-to-cell contact, ruling replacements at amino acid position 26 that conserved
out the involvement of a soluble cytokine. the aromatic nature of this residue had little effect on the
To study the mechanism of Tat-mediated trans-activa- Tat activity, but substitution for Alanine (Y26A) reduced
tion of the LTR promoter in the coculture, we compared the activity to less than 10%. In contrast, any mutation of
the activity of a set of Tat mutants in the intra- versus the Tyrosine residue at position 47 does significantly
inter-cellular assay. We reasoned that if Tat itself is se- reduce the activity to 10–40% of the wild-type Tat protein.
creted and taken up by cells (route 2), Tat mutants should Next, we used this collection of Tat mutants in the inter-
activate the LTR-promoter with approximate equal effi- cellular assay where LTR activation is scored in SupT1
ciency in the two assay systems. On the other hand, if cells, but Tat is produced by COS cells (Fig. 3B). Very
Tat exerts its inter-cellular effect through cofactors that similar activities were measured for the Tat mutants in
this assay compared with the intra-cellular assay. Thisare not involved in intra-cellular trans-activation, some
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FIG. 3. Comparison of the activity spectrum of a set of Tat mutants in the intra-cellular (Top) versus inter-cellular assay (Bottom). LTR activity in
the absence and presence of wild-type Tat (0// wt Tat) is represented by filled bars. The relative promoter activity obtained in the presence of wt
Tat was set at 100%. Activities are means of 3 separate experiments, with less than 25% variation in values between experiments. In a typical
assay, absolute acetylation levels (after subtracting for background counts) were approximately 20,000 and 2,000 cpm for the intra- and inter-cellular
assay, respectively. The Tat mutants are termed according to the position and type of amino acid substitution. The 1-letter amino acid code was
used: Y, tyrosine; F, phenylalanine; W, tryptophan; H, histidine; A, alanine; L, leucine; V, valine. The mutant pairs Y47H1/Y47H2 and Y47A1/Y47A2
encode a similar amino acid (histidine and alanine, respectively), but use different codons.
result is consistent with a direct mechanism of action in Tat mutants and reduced steady state levels of Tat in
the COS donor cells will equally affect the direct andwhich transcriptionally active Tat is exported by COS
cells and taken up into the nucleus of SupT1 T cells indirect routes of inter-cellular Tat action. In order to rule
out this possibility, we performed Western blot analysis(route 2 in Fig. 1).
Amino acid substitutions may affect the stability of the on some of the inactive Tat variants produced in COS
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Tat71 form was verified by Western blot analysis of trans-
fected COS cells (Fig. 5B). Tat71 displayed a somewhat
reduced activity compared with wild-type Tat in the intra-
cellular assay (Fig. 5C), but its activity did not decline
further in the inter-cellular assay. These results demon-
strate that the C-terminus of the Tat protein does not
contribute to either protein secretion or protein uptake.
Inter-cellular transcriptional activation by Tat is
specific for the LTR promoter
The results presented above are consistent with the
idea that Tat itself is secreted and taken up by cells,
suggesting that the molecular mechanism of transcrip-FIG. 4. Western blot analysis of wild-type and mutant Tat proteins.
COS cells were transfected with the indicated pcDNA3-Tat constructs. tional activation is very similar for the intra- versus inter-
mock is a mock-transfected COS cell sample. Total cell extracts were cellular assay. Therefore, LTR promoter mutations within
prepared at 2 days posttransfection and analyzed on a Western blot
the Tat-response element, the TAR RNA hairpin structure,that was stained with Tat MAb 2 (see Materials and Methods). The
should equally interfere with both transcription assays.exon 1 and exon 1 / 2 forms of Tat (respective length of 72 and 86
In contrast, cellular activation pathways can activate theamino acids) are indicated by arrows. The positions of the molecular
mass marker proteins (in kilodaltons) are indicated on the right. LTR promoter in a TAR-independent manner (Harrich et
al., 1990; Taylor et al., 1992). To test the importance of
TAR in inter-cellular LTR-activation, we used TAR variants
cells (Fig. 4). The results demonstrate that the steady with alterations in critical sequences of the single-
state level of these Tat mutants is equivalent to that of stranded loop and bulge elements, mutants Loop135 and
the wild-type Tat protein. Bulge 123, respectively (Berkhout and Jeang, 1991).
These mutants did not support Tat-mediated trans-activa-The second Tat exon is not required for inter-cellular
tion of the LTR promoter in either assay (Fig. 6), consis-trans-activation of the LTR promoter
tent with the notion that a direct Tat-TAR interaction oc-
curs in the SupT1 acceptor cell.Inter-cellular trans-activation requires secretion of Tat
protein by COS cells and uptake of Tat by SupT1 cells Several routes of inter-cellular Tat action do not bring
Tat itself into the nucleus of the acceptor cell, but ratherand the RGD motif within the second Tat exon has been
suggested to play a role in the latter process (Brake et lead to activation of a cellular transcription factor that
activates the LTR promoter (Fig. 1, routes 1, 3, and 4). Ifal., 1990a). To test this idea, we constructed one addi-
tional tat gene mutant with a stopcodon at position 72 such a cellular cofactor is involved, its role can perhaps
be recognized through activation of other transcriptionalat the exon-border (Fig. 5A). Synthesis of the truncated
FIG. 5. The second Tat exon is not required for inter-cellular activity. (A) Schematic representation of full-length Tat and the truncated exon-1
form. A stopcodon was introduced at codon position 72 in the Tat71 mutant. (B) Western blot analysis of Tat protein expression in COS cells
transfected transiently with wt Tat and the Tat71 mutant plasmid. The blot was stained with MAb 4. Wild-type Tat is expressed as the 1-exon and
the 1 / 2 exon form, which are 72 and 86 amino acids in length, respectively. The positions of the molecular mass marker proteins (in kilodaltons)
are indicated. (C) Comparison of the relative activity of wt and truncated Tat71 in the intra- and inter-cellular assay. Activities are means of 3
separate experiments, with less than 25% variation in values between experiments. The activity of wt Tat was set at 100% for each assay (see
legend to Fig. 3 for details).
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FIG. 7. Inter-cellular activation of transcription by Tat is specific for
the HIV-1 LTR promoter. The Tat-responsiveness of three promoters
(SV40 early, CMV immediate early, and the cognate HIV-1 LTR) was
tested in the intra- and inter-cellular assay. Absolute CAT activities are
shown on a logarithmic scale. Actual HIV-1 LTR-induction levels were
450-fold and 8-fold in the intra- and inter-cellular assay, respectively.
promoters that are not responsive to Tat. For instance,
both the SV40 and CMV promoters are not Tat-respon-
sive (Koken et al., 1994; Berkhout and Jeang, 1992), but
the promoter may be influenced by the putative Tat-in-
duced cellular cofactors, e.g., both these promoters
should respond to activation of the NF-kB protein (Wes-
tendorp et al., 1995). Both the weak SV40 and the strong
CMV promoter were not affected by Tat expression in
cocultured cells (Fig. 7, inter-cellular assay), which is the
expected condition if Tat itself exerts the inter-cellular
effects. Similar results were obtained with the Rous sar-FIG. 6. Inter-cellular activation of the HIV-1 LTR promoter by Tat is
coma virus LTR promoter (experiments not shown, seedependent on the TAR RNA motif. Tat-mediated activation of the wild-
type and TAR-mutated HIV-1 LTRs was assayed intra- and inter-cellu- also Fig. 8).
larly. The Loop135 mutant contains a triple substitution in the TAR
loop (CUGGGA to AUUGUA) and Bulge123 contains a mutated bulge Inhibition of inter-cellular trans-activation by Tat
element (UCU to AAG). Plotted is the fold-induction of LTR activity in antibodies
response to Tat, no differences in basal LTR promoter activity was
measured. Antibody-blocking experiments can provide direct evi-
dence for inter-cellular transport of the Tat protein, but
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FIG. 8. Specific inhibition of inter-cellular LTR-activation by antiserum against Tat. (A) Eight Tat antisera were tested for inhibition in the COS-
SupT1 coculture experiment. Tat-antisera 1–8 are specified under Materials and Methods. The Tat activity measured with a mock-treated sample
(0) was set at 100%, corresponding to an 18-fold induction of LTR activity. Normal mouse serum (NMS) was included as an additional control. (B)
The most potent antisera 1, 2, 3, and 4 were pooled and titrated in a coculture experiment with Tat-transfected COS cells and SupT1 cells that
were cotransfected with LTR-CAT and RSV-Luc. A control coculture was performed with mock-transfected COS cells (LTR-CAT 0 Tat). In addition,
the same antiserum mixture was titrated in the intra-cellular assay with LTR-CAT and Tat cotransfected SupT1 cells. The relative CAT/Luciferase
activity measured in the absence of antiserum was set at 100% for each data set.
several attempts failed (Helland et al., 1991; Marcuzzi To prove that the 60% reduction of Tat-induced LTR-
transcription is meaningful and not caused by toxicet al., 1992a). The ability of anti-Tat reagents to absorb
extracellular Tat will depend on several variables, includ- effects of the MAb solution on the cells and their tran-
scriptional capacity, several controls were included ining antibody concentration and affinity. First, we tested
eight Tat antisera (see Table 1) for inhibition of inter- this experiment. First, transcription was also measured
on a cotransfected RSV-Luc plasmid with the Rous sar-cellular LTR-induction (Fig. 8A). Interestingly, several an-
tisera reduced Tat-mediated LTR-transcription to 30– coma virus promoter fused to the Luciferase reporter
gene. In contrast to LTR-Tat-mediated CAT expression,60% of the untreated cells (indicated by the 0 sign) or
the control sample that was treated with normal mouse RSV-promoted Luciferase synthesis was not affected
by the Tat antiserum (Fig. 8B, RSV-Luc). This internalserum (NMS). Based on these results, we mixed the most
potent sera (MAb 1, 2, 3, and 4) and performed a titration control ensures that no differences in transfection and
cell harvest efficiencies are responsible for the ob-experiment. Inter-cellular Tat activity was gradually re-
duced by increasing the antiserum concentration (Fig. served effects. Second, we measured no effect of the
Tat antiserum on the basal LTR promoter activity in8B, LTR-CAT / Tat). However, considerable Tat activity
remained at the highest antiserum concentration. SupT1 cells that were incubated with mock-transfected
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TABLE 1
Tat Antibodies
Tat antiserum (MAb/polyclonal) Repository number Isotype Epitope Reference, contributor
MAb 1 NIH 1973 Unknown 45–64 Drs. Krohn and Ovod
MAb 2 IgG1 Brake et al., 1990b
MAb 3 IgG1 Brake et al., 1990b
MAb 4 IgG1 Brake et al., 1990b
MAb 5 NIH 1976 IgG1 77–86 Drs. Krohn and Ovod
MAb 6 NIH 1974 IgG1 1–16 Drs. Krohn and Ovod
Polyclonal 7 NIH 705 Hauber et al., 1987
MAb 8 MRC 352 IgG1a 1–15 Dingwall et al., 1989
COS cells (Fig. 8B, LTR-CAT 0 Tat). Furthermore, we into cells (Fawell et al., 1994) was efficient with peptides
measured no inhibition by the Tat antisera in the stan- lacking the second coding exon sequences but retaining
dard intra-cellular Tat assay (Fig. 8B, LTR-CAT / Tat, the basic domain of Tat (amino acids 37–72), suggesting
intra-cellular), ruling out an aspecific detrimental effect that the RGD motif does not play a role in this process.
of the antisera on SupT1 cells. This result also indi- Similarly, the effect of extracellular Tat on NF-kB binding
cates that intra-cellular Tat action does not operate via activity was found with the exon-1 domain (amino acids
an autocrine route (see discussion). 1–72) of Tat (Conant et al., 1996) and binding of Tat to
a 90-kDa cell surface protein was observed with the 49–
DISCUSSION 57 domain (Weeks et al., 1993). Furthermore, the RGD
motif is only weakly conserved in different HIV-1 isolatesGiven the diversity of molecular models for inter-cellu-
and absent in the Tat proteins of the HIV-2 viruses andlar Tat action (Fig. 1), we analyzed this mechanism in
the different simian immunodeficiency viruses (SIV)studies with mutant Tat proteins and reporter gene con-
(Jeang, 1995).structs with different promoter motifs. The results of this
In summary, inter-cellular activation of the viral LTRstudy are consistent with the idea that the Tat protein
promoter by Tat involves a transcriptional mechanismitself is (i) secreted, (ii) taken up by neighboring cells,
that is indistinguishable from that of intra-cellular trans-(iii) localized to the nucleus, and (iv) involved in gene-
activation. Our experiments are consistent with the ideaactivation (Fig. 1, route 2). Consistent with this direct
that Tat protein reaches the nucleus of the acceptor cell,pathway, we were able to partially block inter-cellular
where Tat will interact with TAR RNA on nascent HIV-1LTR-activation with Tat antibodies. A recent study reports
transcripts and the cellular transcription machinery tothat Tat antibodies can also block LTR-induction in the
trigger LTR transcription. We do not rule out that theintra-cellular assay, suggesting an autocrine loop for nor-
inter-cellular effects of Tat on cellular genes operatesmal Tat action (Zauli et al., 1995). However, because the
through a distinct mechanism. For instance, whereas in-effect on non-LTR promoters was not tested in the latter
duction of HIV-1 gene expression was observed at highstudy, a more general inhibitory effect on the cellular
Tat concentrations (100 ng/ml), cell-growth promotingtranscriptional capacity was not excluded. The results
effect of Tat was found to peak at 100- to 1000-fold lowerpresented here indicate that Tat antisera do not block the
Tat levels (Ensoli et al., 1993). Whether the extracellularstandard intra-cellular mechanism, and even inhibition of
Tat route has any relevance in vivo remains to be deter-inter-cellular Tat action was not absolute (this study and
mined, but there is some evidence to suggest that theHelland et al., 1991).
paracrine route for Tat-mediated LTR-activation is moreWe tried to separate the ability of Tat to function in
important than previously considered. First, inter-cellularthe intra- versus inter-cellular assay, but all Tat mutants
Tat action in cocultured lymphocytes requires cell–celltested behaved similarly in the two systems. Thus, sofar
contact via the CD4-gp120 interaction (Marcuzzi et al.,we failed to identify Tat ‘‘transport’’ domains that are re-
1992a) and in this system one Tat-producing cell acti-quired specifically for inter-cellular activity. In particular,
vates the LTR-promoter in 100–1000 target cells (Mar-our results indicate that the C-terminal Tat domain includ-
cuzzi et al., 1992b). Second, antibodies to Tat were founding the RGD motif is not critically involved in cellular
to significantly inhibit HIV-1 replication in tissue culture,uptake of the Tat protein, suggesting that integrin recep-
suggesting that extracellular Tat is important for viraltors do not play a role in the cellular uptake of Tat protein.
replication (Steinaa et al., 1994; Re et al., 1995). Third,The observation that the second Tat coding exon, includ-
antibodies that recognize Tat protein are detectable ining the RGD motif, is not required for activity in the inter-
the sera of the majority of seropositive patients (Kronecellular assay is consistent with other published evi-
dence. Tat-mediated delivery of heterologous proteins et al., 1988), suggesting that Tat is released in the course
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